Cost-effectiveness of particle therapy: Current evidence and future needs

被引:42
|
作者
Pijls-Johannesma, Madelon [1 ]
Pommier, Pascal [2 ]
Lievens, Yolande [3 ]
机构
[1] Univ Med Ctr, Maastricht Radiat Oncol MAASTRO Clin, NL-6229 ET Maastricht, Netherlands
[2] Canc Ctr Leon Berard, Dept Radiat Oncol, Lyon, France
[3] Univ Hosp Gasthuisberg, Dept Radiat Oncol, B-3000 Louvain, Belgium
关键词
Particles; Hadron; Ion; Proton; Radiotherapy; Cost-effectiveness; Reimbursement;
D O I
10.1016/j.radonc.2008.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Questions are being raised regarding the cost of particle therapy (PT), and with them criticism that PT is too expensive to allow the expected gain in effectiveness. This paper aims to get more insight in the cost and cost-effectiveness of particle therapy and to discuss a future strategy that allows for critical assessment of this health technology. Material and methods: A systematic literature review based on an earlier published comprehensive review was performed and updated until June 1st 2008. Besides, current business plans of PT projects were examined. Additionally, results retrieved from a cost-simulation tool developed under auspice of the ENLIGHT were discussed. Results: The current literature on cost-effectiveness of PT is scarce, non-comparable, and largely not performed according to standard health technology assessment criteria. Besides, different perspectives for cost evaluations have been used, making it difficult to compare and to determine the relative impact in terms of costs for this new treatment modality. Conclusions: Evidence on the cost-effectiveness of PT is scarce. Adequate reimbursement is necessary to support such innovative yet costly treatments. For now, model-based economic evaluations performed at least from a health care perspective may help us to gain evidence-based insight into cost-effectiveness. (c) 2008 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 89 (2008) 127-134.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 50 条
  • [11] Future costs and the future of cost-effectiveness analysis
    Garber, Alan M.
    Phelps, Charles E.
    JOURNAL OF HEALTH ECONOMICS, 2008, 27 (04) : 819 - 821
  • [12] COST-EFFECTIVENESS OF ANTIHYPERLIPEMIC THERAPY
    KLEVAY, LM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (12): : 1811 - 1811
  • [14] Cost-effectiveness of nutrition therapy
    Correia, Maria Isabel T. D.
    Laviano, Alessandro
    NUTRITION, 2018, 50 : 109 - 111
  • [15] Cost-effectiveness of asthma therapy
    Green, R. J.
    SOUTH AFRICAN FAMILY PRACTICE, 2006, 48 (02) : 44 - 47
  • [16] Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy
    Ganguly, R
    Miller, LS
    Martin, BC
    SCHIZOPHRENIA RESEARCH, 2003, 63 (1-2) : 111 - 119
  • [17] Cost-effectiveness of current antiretroviral regimes
    Anis, AH
    Hogg, RS
    Wang, X
    Yip, B
    Guh, D
    Craib, KJP
    O'Shaughnessy, MV
    Schechter, MT
    Montaner, JSG
    AIDS, 1998, 12 : S15 - S15
  • [18] PACS: current status and cost-effectiveness
    Arenson, RL
    EUROPEAN RADIOLOGY, 2000, 10 (Suppl 3) : S354 - S356
  • [19] PACS: current status and cost-effectiveness
    R. L. Arenson
    European Radiology, 2000, 10 : S354 - S356
  • [20] The potential impact and cost-effectiveness of current and future pneumococcal conjugate vaccines in India
    Farooqui, H. H.
    Jit, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 79 : 134 - 135